Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma.
about
Activin receptor-like kinases: a diverse family playing an important role in cancerKinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma.Role of TGF-β in metastatic colon cancer: it is finally time for targeted therapy.Tumor angiogenesis and vascular normalization: alternative therapeutic targets.Early Actions of Anti-Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels.ALK1 signaling in development and disease: new paradigms.
P2860
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inhibition of ALK1 signaling w ...... tasis in renal cell carcinoma.
@en
Inhibition of ALK1 signaling w ...... tasis in renal cell carcinoma.
@nl
type
label
Inhibition of ALK1 signaling w ...... tasis in renal cell carcinoma.
@en
Inhibition of ALK1 signaling w ...... tasis in renal cell carcinoma.
@nl
prefLabel
Inhibition of ALK1 signaling w ...... tasis in renal cell carcinoma.
@en
Inhibition of ALK1 signaling w ...... tasis in renal cell carcinoma.
@nl
P2093
P2860
P356
P1433
P1476
Inhibition of ALK1 signaling w ...... stasis in renal cell carcinoma
@en
P2093
James W Mier
Jiaxi Song
Marat Alimzhanov
Marcella Callea
Michael B Atkins
Nicolas Solban
Prateek Khanna
R Scott Pearsall
Ravi Kumar
Rupal S Bhatt
P2860
P304
41857-41869
P356
10.18632/ONCOTARGET.9621
P407
P577
2016-07-01T00:00:00Z